-transparent.png){kind=logo}
Lisuride is an ergot derivative with central dopaminergic (D2 agonistic) and serotonergic (5-HT1A agonistic) activity. The effect of lisuride on experimental cerebral infarction in rats was investigated. Cerebral infarction was induced by intracarotid infusion of a 50-microliters mixture in which deformed and rigid red blood cells treated with hypertonic solution were contained. Lisuride or 0.9% NaCl was administered subcutaneously 30 min before induction of cerebral infarction. Lisuride (0.01 mg/kg) not only prolonged the survival time of the animals but also suppressed cerebral edema, increase in the electrolytes content and histological damage in the brain. These results suggest that lisuride has a protective effect against cerebral infarction.
T Miyazawa, and
C Murayama, and
H Nakagawa
June 1985,
Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
T Miyazawa, and
C Murayama, and
H Nakagawa
December 1984,
Archives internationales de pharmacodynamie et de therapie,
T Miyazawa, and
C Murayama, and
H Nakagawa
May 1971,
Neurology,
T Miyazawa, and
C Murayama, and
H Nakagawa
July 1986,
Arzneimittel-Forschung,
T Miyazawa, and
C Murayama, and
H Nakagawa
October 1998,
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
T Miyazawa, and
C Murayama, and
H Nakagawa
August 1972,
Journal of neurology, neurosurgery, and psychiatry,
T Miyazawa, and
C Murayama, and
H Nakagawa
January 1977,
Acta neurologica Scandinavica. Supplementum,
T Miyazawa, and
C Murayama, and
H Nakagawa
July 1959,
Circulation,
T Miyazawa, and
C Murayama, and
H Nakagawa
May 1975,
Casopis lekaru ceskych,
T Miyazawa, and
C Murayama, and
H Nakagawa
January 2020,
Current pharmaceutical biotechnology,
